<p>Eukaryotic elongation factor 2 kinase (eEF2K) is an unusual alpha
kinase whose expression is highly upregulated in various cancers and
contributes to tumor growth, metastasis, and progression. More importantly, expression
of eEF2K is associated with poor clinical outcome and shorter patient survival
triple negative breast cancer (TNBC). Therefore, eEF2K is an emerging molecular
target for development of novel targeted therapeutics and precision medicine in
solid cancers. However, currently potent,
and specific inhibitors of eEF2K are not available for clinical translation. In
the current study, we investigated the effects of various newly designed and
synthesized a series of compounds with coumarin scaffold substitutions in
inhibiting eEF2K activity using <i>in silico
</i>approaches and <i>in vitro </i>studies
in TNBC cells. We utilized an amide substitution at 3-position on the coumarin
ring with their pharmacologically active groups containing pyrrolidine,
piperidine, morpholine and piperazine groups with –(CH<sub>2</sub>)<sub>2</sub>– bridged for aliphatic amides. To evaluate
substituent effects on coumarin scaffold, boronic acid pinacol ester and
boronic acids on phenyl rings were investigated using <i>in silico</i> and <i>in vitro</i>
analyses. Due to their ability to form covalent binding to the target enzyme,
we investigated the effects of boron containing groups on functionalized
coumarin ring (3 compounds) and designed novel aliphatic and aromatic
derivatives of coumarin scaffolds (10 compounds) and phenyl ring with boron
groups <b>(</b>4 compounds<b>)</b>. <i>In
silico</i> analysis and molecular docking studies were performed using the
Glide/SP module of Maestro molecular modeling package. According to obtained
results, structure activity relationship (SAR) was carried out. Among the newly
designed, synthesized, and tested compounds, our <i>in vitro</i> findings revealed that several compounds displayed a
highly effective eEF2K inhibition at submicromolar concentration in<i> in vitro </i>breast cancer cells. In
conclusion, we identified novel eEF2K inhibitors as promising anticancer drug
substance candidates which should be further evaluated by <i>in vivo</i> studies, preclinical and clinical studies.</p><br>